PORTLAND, Ore., June 12, 2017 (GLOBE NEWSWIRE) -- Nobilis Therapeutics announced today that the patent that it had exclusively licensed from Partners HealthCare/McLean Hospital (an affiliate of Harvard University) has received a notice of allowance. The patent is titled "XENON AND/OR ARGON TREATMENT AS AN ADJUNCT TO PSYCHOTHERAPY FOR PSYCHIATRIC DISORDERS" and covers a wide range of noble gas uses in the treatment of psychiatric disorders.
"We are very pleased to receive this very exciting news," said Dr. Vlad Bogin, company's CEO. "This patent had laid the groundwork for our first therapeutic indication, which is post-traumatic stress disorder (PTSD). As Nobilis Therapeutics has selected the 505(b)(2) pathway to NDA approval, having an issued patent becomes of paramount importance."
"The issue of a patent from the United States Patent and Trademark Office strongly supports the novelty of our safe approach to treating this debilitating and devastating condition - more than 20 Veterans a day commit suicide as they try to cope with their traumatic experiences. Sadly, current therapies and treatments are only moderately effective. We are very excited to have forged this relationship with Nobilis Therapeutics as we work to translate our research findings into a clinical trial and, hopefully, an effective treatment for PTSD," said Edward Meloni, Ph.D., one of inventors.
About Nobilis Therapeutics, Inc.
Nobilis Therapeutics is a biotechnology company that is focused on development and commercialization of proprietary inhalation-based treatments using controlled device administration of inert gases that have an exceptional safety profile proven by decades of clinical use. The Company has filed multiple patents on the use of inert gases for treatment of a variety of psychiatric and neurodegenerative diseases and leverages the experience of its international team that has successfully used this technology in the treatment of over 500 patients for conditions ranging from panic attacks to substance abuse.